Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/1571
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMachado, Carmen-
dc.contributor.authorRíos-Villegas, María José-
dc.contributor.authorGálvez-Acebal, Juan-
dc.contributor.authorDomínguez-Castellano, Angel-
dc.contributor.authorFernández-Cuenca, Felipe-
dc.contributor.authorPalomo, Virginia-
dc.contributor.authorMuniain, Miguel Angel-
dc.contributor.authorRodríguez-Baño, Jesús-
dc.date.accessioned2014-04-04T10:01:57Z-
dc.date.available2014-04-04T10:01:57Z-
dc.date.issued2012-10-24-
dc.identifier.citationMachado C, Ríos-Villegas MJ, Gálvez-Acebal J, Domínguez-Castellano A, Fernández-Cuenca F, Palomo V, et al. Long-term outcome of patients after a single interruption of antiretroviral therapy: a cohort study. BMC Res Notes. 2012; 5:578es
dc.identifier.issn1756-0500 (Online)-
dc.identifier.otherPMC3532099-
dc.identifier.urihttp://hdl.handle.net/10668/1571-
dc.descriptionJournal Article; Research Support, Non-U.S. Gov't;es
dc.description.abstractBACKGROUND To describe the long term outcome of patients who interrupted highly active antiretroviral therapy (HAART) once, identify the variables associated with earlier need to re-start HAART, and the response when therapy was resumed. A retrospective observational cohort of 66 adult patients with HIV-1 infection who interrupted HAART with a CD4+cell count ≥ 350 cells/μL and undetectable viral load (VL) was performed. The pre-established CD4+ cell count for restarting therapy was 300cells/μL. Cox regression was used to analyse the variables associated with earlier HAART reinitiation. RESULTS The median follow-up was 209 weeks (range, 64-395). Rates of HIV-related or possible HIV-related events were 0.37 (one case of acute retroviral syndrome) and 1.49 per 100 patient-years, respectively. Two patients died after re-starting therapy and having reached undetectable VL. Three patients suffered a sexually transmitted disease while off therapy. Fifty patients (76%) resumed therapy after a median of 97 weeks (range, 17-267). Age, a nadir of CD4+ <250 cells/μL, and a mean VL during interruption of >10,000 copies/ml were independent predictors for earlier re-start. The intention-to-treat success rate of the first HAART resumed regimen was 85.4%. There were no differences by regimen used, nor between regimens that were the same as or different from the one that had been interrupted. CONCLUSIONS Our data suggest highly active antiretroviral therapy may be interrupted in selected patients because in these patients, when the HAART is restarted, the viral and clinical response may be achieved.es
dc.description.sponsorshipThe Andalusian Public Foundation for the management of Research in Health of Seville (FISEVI). The Ministry of Science and Innovation, Institute Carlos III of Health - co-financed by European Development Regional Fund "A way to achieve Europe" ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD06/0008).es
dc.language.isoenes
dc.publisherBioMed Centrales
dc.relation.ispartofBMC research noteses
dc.subjectHIV-1es
dc.subjectAntiretroviral therapyes
dc.subjectTreatment interruptiones
dc.subjectOutcomees
dc.subjectCohort studyes
dc.subjectFármacos anti-VIHes
dc.subjectTratamiento antirretrovírico de gran actividades
dc.subjectPauta de administración medicamentosaes
dc.subjectInfecciones por VIHes
dc.subjectEstudios retrospectivoses
dc.subjectResultado del tratamientoes
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Anti-HIV Agentses
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Therapy, Combination::Antiretroviral Therapy, Highly Activees
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Administration Schedulees
dc.subject.meshMedical Subject Headings::Check Tags::Femalees
dc.subject.meshMedical Subject Headings::Diseases::Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::HIV Infectionses
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses
dc.subject.meshMedical Subject Headings::Check Tags::Malees
dc.subject.meshMedical Subject Headings::Named Groups::Persons::Age Groups::Adult::Middle Agedes
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies::Retrospective Studieses
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcomees
dc.subject.meshMedical Subject Headings::Named Groups::Persons::Age Groups::Adultes
dc.titleLong-term outcome of patients after a single interruption of antiretroviral therapy: a cohort study.es
dc.typeinfo:eu-repo/semantics/articlees
dc.description.versionYeses
dc.identifier.pmid23095460-
dc.rights.accessRightsAcceso abiertoes
dc.identifier.doi10.1186/1756-0500-5-578-
dc.type.versioninfo:eu-repo/semantics/publishedes
dc.relation.publisherversionhttp://www.biomedcentral.com/1756-0500/5/578/abstractes
dc.contributor.authoraffiliation[Machado,C; Ríos-Villegas,MJ; Gálvez-Acebal,J; Domínguez-Castellano,A; Fernández-Cuenca,F; Palomo,V; Muniain,MA; Rodríguez-Baño,J] Infectious Diseases Unit, Hospital Universitario Virgen Macarena. Seville, Spain. [Ríos-Villegas,MJ; Gálvez-Acebal,J; Domínguez-Castellano,A; Muniain,MA; Rodríguez-Baño,J] Departament of Medicine, University of Seville, Seville, Spain.es
dc.type.subtypeArtículoes
Appears in Collections:01- Artículos - Hospital Virgen Macarena

Files in This Item:
File Description SizeFormat 
machadoC_LongTermOutcomeOfPatients.pdfArtículo publicado567,06 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons